SCHEMBL4724583

SCHEMBL4724583

CCCOc1cccc2[nH][c]c(-c3ccccc3)c12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 2/20 0.37
PDE4A P27815 1/20 0.37
PDE4B Q07343 1/20 0.37
PDE4C Q08493 1/20 0.37
PDE4D Q08499 1/20 0.37
ADRB2 P07550 2/20 0.35
MCHR1 Q99705 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
ABCB1 P08183 1/20 0.34
HTR7 P34969 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
CYP2A6 P11509 1/20 0.33
NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720474 0.93 CYP1A2 (0.42) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4720423 0.89 GRK6 (0.39) PDE5AALDH1A1MEN1KMT2AADORA3
SCHEMBL4720440 0.81 ABCG2 (0.42) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL4720942 0.81 HTR1B (0.41) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4724671 0.75 HTR1B (0.44) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4722616 0.72 ADRB2 (0.39) PDE5APDE4APDE4BPDE4CPDE4D
SCHEMBL4723591 0.69 ENPP1 (0.42) PDE5ALMNATSHR
SCHEMBL14046114 0.69 ADRB2 (0.61) ADRB2ALDH1A1KMT2AADORA3ABCB1
SCHEMBL4723556 0.68 ADORA3 (0.39) ADRB2ALDH1A1NPC1RAB9AMEN1
SCHEMBL30003701 0.68 HTR1B (0.40) ADRB2MCHR1MEN1KMT2AADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 PDE5A 269/4885PDE4A 85/4885PDE4B 128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.